Johnson & Johnson $JNJ Shares Sold by Park National Corp OH

Park National Corp OH trimmed its position in Johnson & Johnson (NYSE:JNJ) by 4.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 121,291 shares of the company’s stock after selling 6,117 shares during the period. Park National Corp OH’s holdings in Johnson & Johnson were worth $32,111,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $28,000. Matrix Trust Co increased its holdings in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares during the period. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth approximately $43,000. Hyposwiss Advisors SA acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $42,000. Finally, Polaris Financial Partners acquired a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on JNJ. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 29th. TD Cowen upped their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. Weiss Ratings raised Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Morgan Stanley boosted their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a report on Thursday, July 16th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.87.

Johnson & Johnson Price Performance

JNJ traded down $1.76 during trading on Monday, hitting $254.27. The company’s stock had a trading volume of 3,866,893 shares, compared to its average volume of 7,974,388. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $612.77 billion, a price-to-earnings ratio of 29.45, a P/E/G ratio of 2.52 and a beta of 0.21. The business’s fifty day simple moving average is $266.37 and its 200 day simple moving average is $248.40. Johnson & Johnson has a twelve month low of $182.94 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is currently 62.11%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 87,569 shares of company stock worth $23,064,544 in the last quarter. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.